Damayanti: The Effectiveness and Safety of Favipiravir in COVID-19 Hospitalized Patients in Bali, Indonesia

The Effectiveness and Safety of Favipiravir in COVID-19 Hospitalized Patients in Bali, Indonesia

Damayanti et al., Kesmas: National Public Health Journal, doi:10.21109/kesmas.v16i4.5433

Damayanti et al., The Effectiveness and Safety of Favipiravir in COVID-19 Hospitalized Patients in Bali, Indonesia, Kesmas: National Public Health Journal, doi:10.21109/kesmas.v16i4.5433

Nov 2021 Source PDF

Twitter
Facebook

All Studies Meta

Retrospective 192 hospitalized patients in Indonesia, 96 patients treated with favipiravir, showing improved recovery with treatment. Only the abstract is currently available. This study is excluded in the after exclusion results of meta analysis: minimal details provided.

Important missing comments or errors? Let us know.

risk of no recovery, 54.5% lower, RR 0.46, p = 0.03, treatment 96, control 96, adjusted per study, inverted to make RR<1 favor treatment.

Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates

Damayanti et al., 1 Nov 2021, retrospective, Indonesia, peer-reviewed, 3 authors.

All Studies Meta Analysis Submit Updates or Corrections

This Paper Favipiravir All

Late treatment
is less effective

Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.

Submit